| name |
Affiliation |
Title |
Topic |
| Avram Hershko |
Technion-Israel Inst. Tech. |
Distinguished Professor |
Roles of the ubiquitin system in health and disease |
| James C. Greenwood |
Biotechnology Industry Organization |
President |
TBD |
| Li Yan |
Merck & Co., Inc. |
Associate Director, Clinical Oncology |
Clinical Development of Monoclonal Antibody Therapeutics |
| Stephen A. Bent |
Foley & Lardner LLP |
Partner |
The Evolving Global Biologics Market: Intellectual Property and Regulatory Considerations. |
| Zeqi Zhou |
Egenix, Inc |
VP and Chief Scientific Office |
Antibody Technology for Immunotherapy of Ovarian Cancer |
| Monique ALRIC |
University of Auvergne |
Professor |
Recombinant living yeasts as a new drug delivery system: in vitro and in vivo validation of the concept and development of oral dosage forms. |
| Kirk R. Smith |
University of California |
Professor |
Climate Change: Mitigating, Adapting, and Suffering -- How Much of Each? |
| Shu Chien |
UCSD |
Professor |
Translational Medicine Global Trend and China Opportunities |
| William J. Rutter |
Synergenics, LLC |
Chairman |
Future Opportunities for the Biotech Industr |
| Erik Kakes |
Applikon Biotechnology BV |
International Sales & Marketing Director |
Innovative technology for cell culture |
| C. Satishchandran |
Nucleonics, Inc. |
Co-Founder, COO & Executive VP |
Advancing RNAi-based Therapeutic from Discovery to clinic |
| Nikolay Alekseevich Zorin |
Institute of Basic Biological Problems,Russian Academy of Sciences |
Principal research scientist |
Thermostable hydrogenase from Thiocapsa roseopersicina: catalytic properties and biotechnological potential. |
| Sailen Barik |
University of South Alabama |
Professor |
Second generation intranasal siRNA therapy |
| Dale M. Edgar |
Eli Lilly & Company |
Executive Director & CSL, Discovery Sleep Research |
Applying In Vivo Discovery Technologies to Improve Patient Outcomes in Sleep Disorders Research |
| Gondi Kumar |
Celgene Corporation |
Senior Director - DMPK |
Contribution of Drug Metabolizing Enzymes to the Inter-individual Variability of Pharmacokinetics |
| Sofie Qiao |
LEAD Therapeutics, Inc. |
President and COO |
LEAD ¨C Designed and Created to Meet Unmet Needs in the Pharmaceutical Industry |
